REFINING OF ASTHMA PREVALENCE SPATIAL DISTRIBUTION AND VISUALIZATION OF OUTDOOR ENVIRONMENT FACTORS USING GIS AND ITS APPLICATION FOR IDENTIFICATION OF MUTUAL ASSOCIATIONS.

Aim: This study presents a procedure of complex assessment of the environment impact on asthma prevalence. This approach is also applicable for any other disease which is supposed to be associated with the quality of the outdoor environment.

Methods: The input data included asthma prevalence values from the National Institute of Public Health (NIPH) cross-section questionnaire survey (13,456 children) and annual reports on activities of all paediatricians in the Czech Republic (2,072 surgeries); concentrations of PM10, PM2.

The influence of age on transfer factor treatment of cellular immunodeficiency, chronic fatigue syndrome and/or chronic viral infections.

A group of 222 patients suffering from cellular immunodeficiency (CID), frequently combined with chronic fatigue syndrome (CFS) and/or chronic viral infections by Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV), were immunologically investigated and treated with transfer factor (TF). The age range was 17-77 years. In order to elucidate the influence of aging on the course of the disease and on treatment, 3 subgroups were formed: 17-43 years, 44-53 years, and 54-77 years.

[Coronary disease in patients after heart transplantation].

Coronary artery lesions are evaluated in a group of 43 patients surviving for more than 3 months after heart transplantation. An angiographic finding was obtained from 35 patients, autopsy findings were available in eight cases. Angiography demonstrated coronary artery lesions in 12 out of the 35 patients whereas autopsy findings were positive in five out of the eight post mortem examinations.

[Infectious complications in patients after heart transplantation].

The incidence of infectious complications was monitored in a group of the first 100 patients undergoing orthotopic heart transplantation at the Institute for Clinical and Experimental Medicine from January 1984 through May 1993. The definition of an infectious complication was a clinically manifest infection requiring treatment. Cytomegalovirus infection and Epstein-Barr virus infection were evaluated by the development of antibody against IgM.